JI

JIN YANG PHARMACEUTICAL. CO., LTD

Develops and manufactures prescription drugs for cancer and metabolic disorders.

007370 | KO

Overview

Corporate Details

ISIN(s):
KR7007370000
LEI:
Country:
South Korea
Address:
서울특별시 서초구 효령로 231, 서울특별시

Description

JIN YANG PHARMACEUTICAL. CO., LTD. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products, with a primary focus on prescription drugs. The company operates a fully automated, high-tech manufacturing facility. Its research and development efforts are dedicated to creating advanced preventive and therapeutic treatments for various diseases. Key areas of R&D include the development of anticancer drugs through molecular biology research, particularly for leukemia, and therapies for metabolic disorders such as diabetes and obesity. The company also develops antivirals and explores formulations based on herbal preparations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-02-27 00:00
[기재정정]현금ㆍ현물배당결정
Korean 15.3 KB
2023-02-27 00:00
주주총회소집결의
Korean 10.4 KB
2023-02-27 00:00
전환가액의조정
Korean 10.6 KB
2023-02-06 00:00
[기재정정]현금ㆍ현물배당결정
Korean 13.8 KB
2023-02-06 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB
2023-01-17 00:00
기타경영사항(자율공시)(다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물 특허권 취득)
Korean 5.5 KB
2022-12-21 00:00
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Korean 38.1 KB
2022-12-19 00:00
현금ㆍ현물배당결정
Korean 9.4 KB
2022-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2022-12-16 00:00
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 5.6 KB
2022-11-18 00:00
[연장결정]주요사항보고서(자기주식취득신탁계약체결결정)
Korean 38.1 KB
2022-11-10 00:00
분기보고서 (2022.09)
Korean 849.1 KB
2022-10-27 00:00
영업(잠정)실적(공정공시)
Korean 14.2 KB
2022-09-21 00:00
자기주식취득결과보고서
Korean 24.2 KB
2022-08-26 00:00
전환가액의조정
Korean 10.1 KB

Automate Your Workflow. Get a real-time feed of all JIN YANG PHARMACEUTICAL. CO., LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JIN YANG PHARMACEUTICAL. CO., LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JIN YANG PHARMACEUTICAL. CO., LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.